Biotech Showcase™ 2016 Interview: Nabriva plans second Phase III trial

February 5, 2016
Having raised just over USD 90 million in an IPO on NASDAQ last year, Nabriva Therapeutics will invest some USD 80 million on two international Phase III trials of its lead pleuromutilin product candidate, lefamulin, to treat community-acquired bacterial pneumonia (CABP). Nabriva CEO Colin Broom tells Mike Ward, Informa Pharma Insights global director of content, that the company is poised to start its second trial in 740 patients which he expects to complete in mid-2017. While the company has ambitions to commercialize lefamulin on its own in the US, it is looking for potential partners for the product in other parts of the world. Also, looking 3–5 years ahead, Nabriva is looking to in-license other assets that would fit its targeted patient focus. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview with Michael W, Young, Klick Health
Biotech Showcase™ 2016: Interview with Michael W, Young, Klick Health

Michael W. Young, VP of Strategy at Klick Health, discusses the top trends in digital health. The informati...

Next Video
Biotech Showcase™ 2016 Interview: Armed with promising clinical data, Abivax seeks partners
Biotech Showcase™ 2016 Interview: Armed with promising clinical data, Abivax seeks partners

Abivax, a French clinical stage antiviral company, is using some of the EUR 58 million it raised in its Jun...